Country versus pharmaceutical company interests for hepatitis C treatment
Year of publication: |
2022
|
---|---|
Authors: | Lothan, Roy ; Gutman, Noa ; Yamin, Dan |
Published in: |
Health care management science : a new journal serving the international health care management community. - Dordrecht [u.a.] : Springer Science + Business Media B.V., ISSN 1572-9389, ZDB-ID 2006272-2. - Vol. 25.2022, 4, p. 725-749
|
Subject: | Cost-effectiveness analysis | Game theory | HCV screening | Healthcare management | Hepatitis C virus | Risk-sharing agreements | Pharmaindustrie | Pharmaceutical industry | Kosten-Wirksamkeits-Analyse | Infektionskrankheit | Infectious disease | Spieltheorie | Gesundheitswesen | Health care system | Arzneimittel | Pharmaceuticals | Gesundheitskosten | Health care costs | Gesundheitsversorgung | Health care |
-
The price of cost-effectiveness thresholds
Brekke, Kurt R., (2023)
-
The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets
Brekke, Kurt R., (2023)
-
Re-thinking global and local manufacturing of medical products after COVID-19
Velásquez, Germán, (2020)
- More ...
-
Incentives' effect in influenza vaccination policy
Yamin, Dan, (2013)
-
Predicting and improving patient-level antibiotic adherence
Rao, Isabelle, (2020)
-
Incentives' Effect in Influenza Vaccination
Gavious, Arieh, (2013)
- More ...